(Q36499247)

14 August 2017

1 reference

title

Effects of 5-fluorouracil adjuvant treatment of colon cancer (English)

1 reference

14 August 2017

1 reference

Wendy Kelder

1

1 reference

PubMed ID

16759168

14 August 2017

Geke A P Hospers

series ordinal

2

1 reference

PubMed ID

16759168

14 August 2017

John T M Plukker

series ordinal

3

1 reference

14 August 2017

1 May 2006

1 reference

Expert Review of Anticancer Therapy

14 August 2017

1 reference

14 August 2017

6

1 reference

14 August 2017

5

1 reference

14 August 2017

785-794

1 reference

Global cancer statistics, 2002

14 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

Estimates of costs and effects of screening for colorectal cancer in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

Genetic alterations in locally advanced stage II/III colon cancer: a search for prognostic markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

pTNM and residual tumor classifications: problems of assessment and prognostic significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

Increase of survival benefit in advanced resectable colon cancer by extent of adjuvant treatment: results of a randomized trial comparing modulation of 5-FU + levamisole with folinic acid or with interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

Capecitabine as adjuvant treatment for stage III colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

Microallelotyping defines the sequence and tempo of allelic losses at tumour suppressor gene loci during colorectal cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

Genetic instabilities in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

Genetic alterations during colorectal-tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

Allelotype of colorectal carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

Microsatellite instability, mismatch repair deficiency, and colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

Lessons from hereditary colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

Colon cancer: survival after curative surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

Colonic stenting: technique, technology, and outcomes for malignant and benign disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

Chemoradiotherapy for colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

No-touch isolation technique in colon cancer: a controlled prospective trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

5-Fluorouracil and folinic acid: interesting biochemistry or effective treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

Systemic therapy for metastatic colorectal cancer: current options, current evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

The novel combination of fat clearance and immunohistochemistry improves prediction of the outcome of patients with colorectal carcinomas: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

Micrometastases and survival in stage II colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

Ultrastaging of early colon cancer using lymphatic mapping and molecular analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

Intraoperative sentinel lymph node mapping in patients with colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

Gene expression profiling predicts clinical outcome of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

A molecular signature of metastasis in primary solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

A gene-expression signature as a predictor of survival in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

Thymidylate synthase expression and prognosis of patients with gastrointestinal cancers receiving adjuvant chemotherapy: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

Safe administration of irinotecan, oxaliplatin and raltitrexed in a DPD-deficient patient with metastatic colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.785

21 January 2018

Identifiers

DOI

10.1586/14737140.6.5.785

1 reference

14 August 2017

1 reference

PubMed ID

16759168